<DOC>
	<DOCNO>NCT01496469</DOCNO>
	<brief_summary>The purpose study evaluate effect febuxostat , daily ( QD ) , compare placebo lower ambulatory 24-hour mean blood pressure participant hypertension hyperuricemia ( associate gout ) .</brief_summary>
	<brief_title>Effect Febuxostat Blood Pressure</brief_title>
	<detailed_description>This study design evaluate effect febuxostat 6 week treatment .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<criteria>1 . The participant document hypertension , define average clinic systolic blood pressure ( SBP ) ≥145 mm Hg ≤165 mm Hg average clinic diastolic blood pressure ( DBP ) ≥90 mm Hg ≤105 mm Hg Day 21 Screening Visit ; average BP measurement two three Placebo Runin Visits ( Day 14 , Day 7 Day 1 ) must also meet criterion hypertension . 2 . The participant serum uric acid ( sUA ) level ≥7.0 mg/dL associate gout , Day 21 Screening Visit . 3 . The participant 24hour mean ambulatory SBP ≥130 mm Hg &lt; 165 mm Hg Baseline ( Day 1 ) Visit . 4 . At initial Screening Visit ( Day 21 ) , maximum number antihypertensive medication participant take ≤ 2 ( fixeddose combination medication consider 2 medication , include diuretic ) , participant stable dose medication least1 month prior start initial Screening Visit ( Day 21 ) . 5 . The participant male least 18 year age , female : Surgically sterilize ( hysterectomy , bilateral oophorectomy tubal ligation ) , OR Postmenopausal ( define least 1 year since last regular menses folliclestimulating hormone ( FSH ) &gt; 40 IU/L , least 5 year since last regular menses ) , OR On hormone replacement therapy ≥ 55 year age . 6 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 7 . In opinion investigator , participant capable understand comply protocol requirement . 1 . The participant receive investigational compound within 30 day , within 5 halflives compound ( whichever longer ) prior Screening Visit . 2 . The participant receive febuxostat uratelowering therapy ( ULT ) previous clinical study therapeutic agent . 3 . The participant gout , history gout , gout flare . 4 . The participant secondary hyperuricemia ( HPU ) ( e.g. , due myeloproliferative disorder , organ transplant ) . 5 . The participant know secondary hypertension etiology ( e.g. , renovascular disease , primary hyperaldosteronism , Cushing syndrome ) . 6 . The participant history , within 6 month prior screen , myocardial infarction , heart failure , unstable angina , coronary artery bypass graft , percutaneous coronary intervention . 7 . The participant irregular cardiac rhythm ( e.g. , atrial fibrillation , multifocal premature atrial contraction ) lead difficulty interpretation ambulatory blood pressure monitoring ( ABPM ) . 8 . The participant history congestive heart failure , hypertensive encephalopathy , cerebrovascular accident , transient ischemic attack . 9 . The participant type 1 poorly control type 2 diabetes mellitus ( glycosylated hemoglobin [ HbA1c ] &gt; 8.0 % ) Screening . 10 . The participant history infection hepatitis B , hepatitis C , human immunodeficiency virus . 11 . The participant average clinic SBP &gt; 165 mm Hg DBP &gt; 105 mm Hg 1 visit Placebo Runin Period . 12 . The participant 's average clinic SBP DBP measurement increase decrease &gt; 10 mm Hg Placebo Runin visit ( Day 14 Day 7 , Day 7 Day 1 , Day 14 Day 1 ) . 13 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 14 . The participant alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) value great 2.0 time upper limit normal ( ULN ) . 15 . The participant significant medical condition and/or condition would interfere treatment , safety compliance protocol . 16 . The participant history alcoholism illicit drug abuse within 5 year prior Screening Visit currently consume &gt; 14 alcoholic drink per week . 17 . The participant know hypersensitivity allergy febuxostat component formulation compound . 18 . The participant taking expect take medication describe excluded medication section . 19 . The participant history cancer remission least 5 year prior first dose study drug . This criterion apply participant successfully resect basal cell stage I squamous cell carcinoma skin . 20 . The participant 's estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m3 , eGFR calculated Central Laboratory use Modification Diet Renal Disease ( MDRD ) formula Day 21 Screening Visit . 21 . The participant noncompliant ( &lt; 80 % &gt; 120 % ) study medication Placebo RunIn Period . 22 . The participant upper arm circumference le 24 cm great 42 cm . 23 . The participant 's work shift include hour 11 PM ( 2300 ) 7 AM ( 0700 ) . 24 . The participant baseline 24hour ABPM reading insufficient quality ( describe Appendix F protocol ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>